Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens
- Citation:
- Int J Cancer vol 150 (2) 279-89
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 11
- Parents:
- None
- Children:
- None
- Pharmas:
- Genentech (all); Bristol-Myers Squibb and Pfizer (CALGB 80405)
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233373, U10CA180863 (CCTG), São Paulo Research Foundation-FAPESP (2018/04491-2)
- Corr. Author:
- Authors:
- Julia C.F. Quintanilha Jin Wang Alexander B. Sibley Wei Xu Osvaldo Espin-Garcia Chen Jiang Amy S. Etheridge Mark J. Ratain Heinz-Josef Lenz Monica Bertagnolli Hedy L. Kindler Maura N. Dickler Alan Venook Geoffrey Liu Kouros Owzar Danyu Lin Federico Innocenti
- Networks:
- 11030, CA011, CA136, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-40503, CALGB-80303, CALGB-80405, ICON7
- Phases:
- 3
- Keywords: